Replies to post #137520 on Biotech Values

[ronpopeil]

What if the data from the low dose arm are better than from the high dose arm?

The press release states that the high-dose arm generated "greater efficacy" in the high-dose arm

[Summer2762]

For example, why do you think they grouped the two treatment arms together in the analysis?

Because that's the primary endpoint. I would have shouted foul if the arms were reported separately.